ITMI20050336A1 - Formulazione ad attivita' anti-tumorale - Google Patents

Formulazione ad attivita' anti-tumorale

Info

Publication number
ITMI20050336A1
ITMI20050336A1 IT000336A ITMI20050336A ITMI20050336A1 IT MI20050336 A1 ITMI20050336 A1 IT MI20050336A1 IT 000336 A IT000336 A IT 000336A IT MI20050336 A ITMI20050336 A IT MI20050336A IT MI20050336 A1 ITMI20050336 A1 IT MI20050336A1
Authority
IT
Italy
Prior art keywords
formulation
tumor activity
tumors
produced
oligotide
Prior art date
Application number
IT000336A
Other languages
English (en)
Inventor
Gunther Eissner
Laura Iris Ferro
Massimo Iacobelli
Original Assignee
Gentium Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium Spa filed Critical Gentium Spa
Priority to IT000336A priority Critical patent/ITMI20050336A1/it
Priority to US11/817,572 priority patent/US20080194506A1/en
Priority to AT07117228T priority patent/ATE514427T1/de
Priority to US11/817,575 priority patent/US20080194507A1/en
Priority to CNA2006800065739A priority patent/CN101232892A/zh
Priority to EP06708537A priority patent/EP1855697A2/en
Priority to PCT/EP2006/060306 priority patent/WO2006094917A2/en
Priority to JP2007557485A priority patent/JP5714203B2/ja
Priority to CA2598072A priority patent/CA2598072C/en
Priority to KR1020077021110A priority patent/KR20070120953A/ko
Priority to BRPI0607833A priority patent/BRPI0607833A2/pt
Priority to PT07117228T priority patent/PT1867335E/pt
Priority to CA002598613A priority patent/CA2598613A1/en
Priority to MX2007010754A priority patent/MX2007010754A/es
Priority to JP2007557486A priority patent/JP2008531647A/ja
Priority to MX2007010407A priority patent/MX2007010407A/es
Priority to AU2006222044A priority patent/AU2006222044A1/en
Priority to AU2006222045A priority patent/AU2006222045B2/en
Priority to ZA200707417A priority patent/ZA200707417B/xx
Priority to CNA2006800055559A priority patent/CN101123973A/zh
Priority to KR1020077023861A priority patent/KR20070121001A/ko
Priority to PCT/EP2006/060304 priority patent/WO2006094916A1/en
Priority to BRPI0608259A priority patent/BRPI0608259A2/pt
Priority to CNA2008100822369A priority patent/CN101254204A/zh
Priority to EP07117228A priority patent/EP1867335B1/en
Priority to EP06708536A priority patent/EP1853277A1/en
Priority to ES07117228T priority patent/ES2366486T3/es
Priority to KR1020077021114A priority patent/KR20070120954A/ko
Priority to DK07117228.2T priority patent/DK1867335T3/da
Publication of ITMI20050336A1 publication Critical patent/ITMI20050336A1/it
Priority to IL185181A priority patent/IL185181A0/en
Priority to IL185182A priority patent/IL185182A0/en
Priority to IL185258A priority patent/IL185258A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
IT000336A 2005-03-03 2005-03-03 Formulazione ad attivita' anti-tumorale ITMI20050336A1 (it)

Priority Applications (32)

Application Number Priority Date Filing Date Title
IT000336A ITMI20050336A1 (it) 2005-03-03 2005-03-03 Formulazione ad attivita' anti-tumorale
MX2007010407A MX2007010407A (es) 2005-03-03 2006-02-27 Formulacion con accion anti-tumor.
CNA2008100822369A CN101254204A (zh) 2005-03-03 2006-02-27 用于治疗血管生成依赖性肿瘤的去纤苷酸和/或寡脱氧核糖核苷酸
US11/817,575 US20080194507A1 (en) 2005-03-03 2006-02-27 Defibrotide An/Or Oligodeoxyribonucleotides For Treating Angiogenesis-Dependent Tumors
CNA2006800065739A CN101232892A (zh) 2005-03-03 2006-02-27 用于治疗血管生成依赖性肿瘤的去纤苷酸和/或寡脱氧核糖核苷酸
EP06708537A EP1855697A2 (en) 2005-03-03 2006-02-27 Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors
PCT/EP2006/060306 WO2006094917A2 (en) 2005-03-03 2006-02-27 Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors
AU2006222045A AU2006222045B2 (en) 2005-03-03 2006-02-27 Oligodeoxyribonucleotides of 4000-10000 Dalton for treating tumors
CA2598072A CA2598072C (en) 2005-03-03 2006-02-27 Formulations with anti-tumour action
KR1020077021110A KR20070120953A (ko) 2005-03-03 2006-02-27 항암활성을 갖는 제제
BRPI0607833A BRPI0607833A2 (pt) 2005-03-03 2006-02-27 uso de defibrotídeo e/ou oligodesoxirribonucleotídeos
PT07117228T PT1867335E (pt) 2005-03-03 2006-02-27 Oligodesoxirribonucleótidos combinados com rapamicina para tratamento do cancro
CA002598613A CA2598613A1 (en) 2005-03-03 2006-02-27 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
MX2007010754A MX2007010754A (es) 2005-03-03 2006-02-27 Defibrotide y/u oligodeoxiribonucleotidos para tratar tumores dependientes de angiogenesis.
JP2007557486A JP2008531647A (ja) 2005-03-03 2006-02-27 抗腫瘍作用を有する製剤
US11/817,572 US20080194506A1 (en) 2005-03-03 2006-02-27 Oligodeoxyribonuleotides of 4000-10000 Dalton for Treating
AU2006222044A AU2006222044A1 (en) 2005-03-03 2006-02-27 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
JP2007557485A JP5714203B2 (ja) 2005-03-03 2006-02-27 血管新生依存性腫瘍を治療するためのデフィブロチドおよび／またはオリゴデオキシリボヌクレオチド
ZA200707417A ZA200707417B (en) 2005-03-03 2006-02-27 Oligodeoxyribonucleotides of 4000-10000 Dalton for treating tumors
CNA2006800055559A CN101123973A (zh) 2005-03-03 2006-02-27 用于治疗肿瘤的4000-10000道尔顿的寡脱氧核糖核苷酸
KR1020077023861A KR20070121001A (ko) 2005-03-03 2006-02-27 신혈관 형성-의존성 종양 치료용 약학적 제제
PCT/EP2006/060304 WO2006094916A1 (en) 2005-03-03 2006-02-27 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
BRPI0608259A BRPI0608259A2 (pt) 2005-03-03 2006-02-27 uso de oligodesoxírribonucleotídeos
AT07117228T ATE514427T1 (de) 2005-03-03 2006-02-27 Oligonukleotide kombiniert mit rapamycin zur behandlung von krebs
EP07117228A EP1867335B1 (en) 2005-03-03 2006-02-27 Oligodeoxyribonucleotides combined with rapamycin for treating cancer
EP06708536A EP1853277A1 (en) 2005-03-03 2006-02-27 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
ES07117228T ES2366486T3 (es) 2005-03-03 2006-02-27 Oligodesoxirribonucleótidos combinados con rapamicina para el tratamiento del cáncer.
KR1020077021114A KR20070120954A (ko) 2005-03-03 2006-02-27 신혈관 형성-의존성 종양 치료용 약학적 제제
DK07117228.2T DK1867335T3 (da) 2005-03-03 2006-02-27 Oligodeoxyribonukleotider kombineret med rapamycin til behandling af cancer
IL185181A IL185181A0 (en) 2005-03-03 2007-08-09 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
IL185182A IL185182A0 (en) 2005-03-03 2007-08-09 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
IL185258A IL185258A (en) 2005-03-03 2007-08-14 Oligodeoxyribonucleotides for use in the treatment of angiogenesis-dependent tumors in human

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000336A ITMI20050336A1 (it) 2005-03-03 2005-03-03 Formulazione ad attivita' anti-tumorale

Publications (1)

Publication Number Publication Date
ITMI20050336A1 true ITMI20050336A1 (it) 2006-09-04

Family

ID=39085989

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000336A ITMI20050336A1 (it) 2005-03-03 2005-03-03 Formulazione ad attivita' anti-tumorale

Country Status (9)

Country Link
EP (1) EP1867335B1 (it)
CN (3) CN101232892A (it)
AT (1) ATE514427T1 (it)
BR (2) BRPI0607833A2 (it)
DK (1) DK1867335T3 (it)
ES (1) ES2366486T3 (it)
IT (1) ITMI20050336A1 (it)
PT (1) PT1867335E (it)
ZA (1) ZA200707417B (it)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1252174B (it) * 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
CA2259041A1 (en) * 1997-04-28 1998-11-05 Arsinur Burcoglu Method of treating hiv infection and related secondary infections thereof
EP0985035A2 (en) * 1997-05-30 2000-03-15 McGILL UNIVERSITY Dna methyltransferase genomic sequences and antisense oligonucleotides
DE19740384A1 (de) * 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN

Also Published As

Publication number Publication date
ATE514427T1 (de) 2011-07-15
BRPI0607833A2 (pt) 2017-05-30
BRPI0608259A2 (pt) 2016-10-11
EP1867335A2 (en) 2007-12-19
CN101123973A (zh) 2008-02-13
CN101254204A (zh) 2008-09-03
EP1867335B1 (en) 2011-06-29
PT1867335E (pt) 2011-09-06
CN101232892A (zh) 2008-07-30
ES2366486T3 (es) 2011-10-20
EP1867335A3 (en) 2008-03-12
DK1867335T3 (da) 2011-08-01
ZA200707417B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
MX2007010407A (es) Formulacion con accion anti-tumor.
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
WO2007019308A3 (en) Illudin analogs useful as anticancer agents
ATE492651T1 (de) Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
DOP2011000199A (es) Compuestos heterociclocos y metodos de uso
DK2092065T3 (da) Antisense-forbindelser
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
GT200600092A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
BRPI0813625A2 (pt) Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5
MX2009007345A (es) Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo.
WO2008155421A3 (en) Indolin-2-ones and aza-indolin-2-ones
PA8632601A1 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2009047568A3 (en) In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells
BRPI0506535A (pt) pirroles bis-indole úteis como agentes anti-microbiais
WO2006091965A3 (en) Nod1 as an anti-tumor agent
WO2009105457A3 (en) Slit2 cancer markers
ITMI20050336A1 (it) Formulazione ad attivita' anti-tumorale
EA200971103A1 (ru) Иммуноцитокины для лечения рака в сочетании с химиотерапевтическими агентами
WO2012006563A3 (en) Novel daidzein analogs as treatment for cancer
PT1606233E (pt) Derivados de esteres lipidicos de nucleotidos
WO2006089218A3 (en) Methods and compositions for modulating angiogenesis
DE602007003314D1 (de) Immunmodulierendes Antikrebsmittel
WO2004062586A3 (en) Antineoplastic ether lipid compounds